News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Arena Pharmaceuticals, Inc. (ARNA) Expands Deal With Eisai Inc. (ESALF.PK) on Sales of Obesity Drug



11/8/2013 7:05:53 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Arena Pharmaceuticals Inc. (ARNA) said it expanded its marketing agreement with Eisai (4523) Co. for the diet drug Belviq and received an upfront payment of $60 million. Eisai, based in Tokyo, will now market the product in all countries except South Korea, Taiwan, Australia, Israel, and New Zealand, San Diego-based Arena said today in statement. The two companies received approval from the Food and Drug Administration in June 2012 to market the diet pill in the U.S. and clearance from the Drug Enforcement Agency to start sales in May.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg
Read at Reuters
Read at News Release


comments powered by Disqus
   
Obesity

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES